Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids
Authors:
- 1 June 2007
- journal article
- Vol. 2 (2) , 157-167
Abstract
Patients with COPD are frequently prescribed inhaled corticosteroids (ICS); however, it is unclear whether the treatment with ICS might modify responses to inhaled bronchodilators. Two 6-month, randomized, placebo-controlled, double-blind, double-dummy, parallel-group studies of tiotropium 18 μg once daily, compared with salmeterol, 50 μg bid, had been conducted in patients with moderate-to-severe COPD. Efficacy was assessed by spirometry, transition dyspnea index (TDI), St. George’s Respiratory Questionnaire (SGRQ), and exacerbations. Data from both studies were combined to form subgroups with regard to concurrent use of ICS. 796 patients receiving ICS were separately analyzed from 390 patients not receiving ICS. Mean age was 64 years, and pre-bronchodilator FEV1 was 1.06 L (ICS group) and 1.13 L (non-ICS group). Both bronchodilators increased morning mean ± SE pre-dose FEV1 compared with placebo (ICS groups: tiotropium 110 ± 20 mL, salmeterol 80 ± 20 mL; non-ICS groups: tiotropium 150 ± 30 mL, salmeterol 110 ± 30 mL; p > 0.05 for tiotropium vs salmeterol). Improvements in TDI and SGRQ and frequency of exacerbations also tended to be more profound for tiotropium. Treatment with tiotropium in patients with moderate-to-severe COPD was superior to salmeterol in lung function, irrespective of concurrent use of ICS.Keywords
This publication has 60 references indexed in Scilit:
- Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatmentEuropean Respiratory Journal, 2006
- Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEuropean Respiratory Journal, 2005
- Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trialThorax, 2005
- Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary diseaseEuropean Respiratory Journal, 2003
- Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax, 2003
- Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialThe Lancet, 2003
- Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax, 2002
- Long acting beta 2 agonists and theophylline in stable chronic obstructive pulmonary diseaseThorax, 1999
- Tiotropium (SPIRIVA™): Mechanistical considerations and clinical profile in obstructive lung diseaseLife Sciences, 1999
- Role of the Parasympathetic System in Airway Obstruction Due to EmphysemaNew England Journal of Medicine, 1984